Questions 91–100

  • Yousaf Ali


This chapter illustrates a variety of different scenarios of rheumatic disease in succinct question and answer format. It contains ten complex cases with potentially unusual diagnoses designed to stimulate thought and further reading in this rapidly evolving specialty.


Assessment of rheumatic diseases Complex rheumatology cases Rare rheumatic diseases Rheumatology board exam preparation Rheumatology case studies Study guide for rheumatology 


  1. 1.
    Tomas MB, Patel M, Marwin SE, Palestro CJ. The diabetic foot. Br J Radiol. 2000;73(868):443–50. ReviewCrossRefPubMedGoogle Scholar
  2. 2.
    Crum NF, Lederman ER, Wallace MR. Infections associated with tumor necrosis factor-alpha antagonists. Medicine. 2005;84(5):291–302. ReviewCrossRefPubMedGoogle Scholar
  3. 3.
    Flynn JL, Goldstein MM, Chan J, Triebold KJ, Pfeffer K, Lowenstein CJ, Schreiber R, Mak TW, Bloom BR. Tumor necrosis factor-α is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity. 1995;2:561–72.CrossRefPubMedGoogle Scholar
  4. 4.
    Hamilton CD. Tuberculosis in the cytokine era: what rheumatologists need to know. Arthritis Rheum. 2003;48(8):2085–91. ReviewCrossRefPubMedGoogle Scholar
  5. 5.
    Reveille JD, Arnett FC. Spondyloarthritis: update on pathogenesis and management. Am J Med. 2005;118(6):592–603. ReviewCrossRefPubMedGoogle Scholar
  6. 6.
    Lockshin MD. Update on antiphospholipid syndrome. Bull NYU Hosp Jt Dis. 2006;64(1–2):57–9.PubMedGoogle Scholar
  7. 7.
    Franklin J, Lunt M, Bunn D, Symmons D, Silman A. Incidence of lymphoma in a large primary care derived cohort of cases of inflammatory polyarthritis. Ann Rheum Dis. 2006;65:617–22.CrossRefPubMedGoogle Scholar
  8. 8.
    Wolfe F, Michaud K. Lymphomain rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum. 2004;50(6):1740–51.CrossRefPubMedGoogle Scholar
  9. 9.
    Mercer LK, Galloway JB, Lunt M, et al. Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis Annals of the Rheumatic Diseases. Published Online First: 08 August 2016. doi: 10.1136/annrheumdis-2016-209389.CrossRefPubMedGoogle Scholar
  10. 10.
    Alpagut U, Ugurlucan M, Dayioglu E. Major arterial involvement and review of Behcet’s disease. Ann Vasc Surg. 2007;21(2):232–9. ReviewCrossRefPubMedGoogle Scholar
  11. 11.
    Uzun O, Akpolat T, Erkan L. Pulmonary vasculitisin Behcet disease: a cumulative analysis. Chest. 2005;127(6):2243–53. ReviewCrossRefPubMedGoogle Scholar
  12. 12.
    Yazici H, Fresko I, Yurdakul S. Behçet’s syndrome: disease manifestations, management, and advances in treatment. Nat Clin Pract Rheumatol. 2007;3(3):148–55. ReviewCrossRefPubMedGoogle Scholar
  13. 13.
    Dember LM, Jaber BL. Dialysis-related amyloidosis: late finding or hidden epidemic? Semin Dial. 2006;19(2):105–9. ReviewCrossRefPubMedGoogle Scholar
  14. 14.
    Wilson SW, Pollard RE, Lees VC. Management of carpal tunnel syndrome in renal dialysis patients using an extended carpal tunnel release procedure. J Plast Reconstr Aesthet Surg. 2008;61(9):1090–4.CrossRefPubMedGoogle Scholar
  15. 15.
    Jutkowitz E, Dubreuil M, Lu N, et al. The cost-effectiveness of HLA-B*5801 screening to guide initial urate-lowering therapy for gout in the United States. Semin Arthritis Rheum. 2017;46(5):594–600.CrossRefPubMedGoogle Scholar
  16. 16.
    Saito Y, Stamp LK, Caudle KE, Hershfield MS, et al. Clinical pharmacogenetics implementation consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update. Clin Pharmacol Ther. 2015;99(1):36–7.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Stamp LK, Taylor WJ, Jones PB, Dockerty JL, et al. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum. 2012;64(8):2529–36.CrossRefPubMedGoogle Scholar
  18. 18.
    Mert A, Kumbasar H, Ozaras R, Erten S, Tasli L, Tabak F, Ozturk R. Erythema nodosum: an evaluation of 100 cases. Clin Exp Rheumatol. 2007;25(4):563–70.PubMedGoogle Scholar
  19. 19.
    Mert A, Ozaras R, Tabak F, Pekmezci S, Demirkesen C, Ozturk R. Erythema nodosum: an experience of 10 years. Scand J Infect Dis. 2004;36(6–7):424–7.CrossRefPubMedGoogle Scholar
  20. 20.
    Do Carmo I, Mascarenhas M, Macedo A, Silva A, Santos I, Bouça D, Myatt J, Sampaio D. A study of bone density change in patients with anorexia nervosa. Eur Eat Disord Rev. 2007;15(6):457–62.CrossRefPubMedGoogle Scholar
  21. 21.
    Wolfert A, Mehler PS. Osteoporosis: prevention and treatment in anorexia nervosa. Eat Weight Disord. 2002;7(2):72–81. ReviewCrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Yousaf Ali
    • 1
  1. 1.Mount Sinai HospitalNew YorkUSA

Personalised recommendations